Evidence map›Paper›PMID 38650175›Full record

ArticleMolecular oncology2024

Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues.

Andrea Vallés-Martí, Richard R de Goeij-de Haas, Alex A Henneman, Sander R Piersma, Thang V Pham, Jaco C Knol, Joanne Verheij, Frederike Dijk, Hans Halfwerk, Elisa Giovannetti and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Bioinformatics-based prognostic value andFrontiers in oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Andrea Vallés-MartíDepartment of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.ORCID 0000-0002-6557-0130
Richard R de Goeij-de HaasDepartment of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.
Alex A HennemanDepartment of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.
Sander R PiersmaDepartment of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.
Thang V PhamDepartment of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.
Jaco C KnolDepartment of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.
Joanne VerheijDepartment of Pathology, Amsterdam University Medical Center, The Netherlands.
Frederike DijkDepartment of Pathology, Amsterdam University Medical Center, The Netherlands.
Hans HalfwerkDepartment of Pathology, Amsterdam University Medical Center, The Netherlands.
Elisa GiovannettiDepartment of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.ORCID 0000-0002-7565-7504
Connie R JiménezDepartment of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.ORCID 0000-0002-3103-4508
Maarten F BijlsmaCancer Biology, Cancer Center Amsterdam, The Netherlands.ORCID 0000-0001-6627-3229
Oncode Institute · NLAmsterdam University Medical Centers · NLDutch Cancer Society · NL

Funding

KWF Kankerbestrijding KWF 2016-1Nederlandse Organisatie voor Wetenschappelijk Onderzoek 91116017
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited number of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides a direct read-out of aberrant signaling and the resultant clinically relevant phenotype. Mass spectrometry (MS)-based proteomics and phosphoproteomics were applied to 42 PDAC tumors. Data encompassed over 19 936 phosphoserine or phosphothreonine (pS/T; in 5412 phosphoproteins) and 1208 phosphotyrosine (pY; in 501 phosphoproteins) sites and a total of 3756 proteins. Proteome data identified three distinct subtypes with tumor intrinsic and stromal features. Subsequently, three phospho-subtypes were apparent: two tumor intrinsic (Phos1/2) and one stromal (Phos3), resembling known PDAC molecular subtypes. Kinase activity was analyzed by the Integrative iNferred Kinase Activity (INKA) scoring. Phospho-subtypes displayed differential phosphorylation signals and kinase activity, such as FGR and GSK3 activation in Phos1, SRC kinase family and EPHA2 in Phos2, and EGFR, INSR, MET, ABL1, HIPK1, JAK, and PRKCD in Phos3. Kinase activity analysis of an external PDAC cohort supported our findings and underscored the importance of PI3K/AKT and ERK pathways, among others. Interestingly, unfavorable patient prognosis correlated with higher RTK, PAK2, STK10, and CDK7 activity and high proliferation, whereas long survival was associated with MYLK and PTK6 activity, which was previously unknown. Subtype-associated activity profiles can guide therapeutic combination approaches in tumor and stroma-enriched tissues, and emphasize the critical role of parallel signaling pathways. In addition, kinase activity profiling identifies potential disease markers with prognostic significance.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAgedCell Line, TumorFemaleHumansMaleMiddle AgedPhosphorylationPrognosisProteomicskinase activitypancreatic ductal adenocarcinomapersonalized medicinephosphoproteome

Identifiers

PMID38650175
PMCPMC11306541
OpenAlexW4395045562

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.